Analyzing Rhythm Pharmaceuticals (RYTM) & Its Peers

Rhythm Pharmaceuticals (NASDAQ: RYTM) is one of 290 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Rhythm Pharmaceuticals to similar businesses based on the strength of its valuation, institutional ownership, risk, profitability, analyst recommendations, earnings and dividends.


This table compares Rhythm Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Rhythm Pharmaceuticals N/A N/A N/A
Rhythm Pharmaceuticals Competitors -5,401.89% -161.60% -35.74%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Rhythm Pharmaceuticals and its peers, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rhythm Pharmaceuticals 0 1 3 0 2.75
Rhythm Pharmaceuticals Competitors 1142 3445 11950 241 2.67

Rhythm Pharmaceuticals currently has a consensus price target of $31.25, suggesting a potential upside of 16.13%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 42.00%. Given Rhythm Pharmaceuticals’ peers higher probable upside, analysts clearly believe Rhythm Pharmaceuticals has less favorable growth aspects than its peers.

Insider and Institutional Ownership

49.6% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 16.9% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Rhythm Pharmaceuticals and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Rhythm Pharmaceuticals N/A -$25.87 million N/A
Rhythm Pharmaceuticals Competitors $290.27 million $35.99 million 52.16

Rhythm Pharmaceuticals’ peers have higher revenue and earnings than Rhythm Pharmaceuticals.


Rhythm Pharmaceuticals peers beat Rhythm Pharmaceuticals on 6 of the 11 factors compared.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity. Setmelanotide serves as replacement therapy for the treatment of melanocortin-4, or MC4, pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity. The Company also focused on obesity related to six single gene-related, or monogenic, MC4 pathway deficiencies pro-opiomelanocortin, or POMC, leptin receptor, or LepR, Bardet-Biedl syndrome, Alstrom syndrome, POMC heterozygous, and POMC epigenetic disorders.

Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply